- POSITIVE
Annual Revenue Walpar Nutritions Mar-2026 Annual Revenue is Rs 65 Cr which is growth of 8.6% YoY.
- POSITIVE
Annual Net Profit Walpar Nutritions Mar-2026 Annual Net Profit is Rs 2 Cr which is growth of 16.1% YoY.
aboutWalpar Nutritions Ltd. is an India-based company specializing in the manufacturing and marketing of nutraceuticals, herbal, and ayurvedic products. The company operates as a contract manufacturer and also markets its own brand, focusing on health sup... Read More
25.00-1.10(-4.21%)
2,000
NSE Volume
NSE 28 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Check Before You Buy
VIEW FULL CHECKLISTHigh rank
7Positive7Negative
50.0%Pass in checklist
Check P/E Buy Sell Zone
Not enough data available
Walpar Nutritions Stock Price Analysis
Day Price Range-4.2% 1 Day return | 25 (LTP) 2525 LowHigh |
|---|---|
Week Price Range-4.2% 1 Week return | 25 (LTP) 2526.1 LowHigh |
Month Price Range-8.8% 1 Month return | 25 (LTP) 2529 LowHigh |
52 Week Price Range-43.2% 1 Year return | 25 (LTP) 21.250.6 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Walpar Nutritions annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
31.1% | 60.7% | 65.4 | 60.3 | 51.4 | 29 | 26.8 | 6.1 | 16.7 | 12.8 | 6.5 | ||
Operating Exp. Ann. | 30.8% | 62% | 62.4 | 57.3 | 49.6 | 27.9 | 25.7 | 5.6 | 15.5 | 12 | 6 | |
Operating Profit Ann. | 53.6% | 42.1% | 2.9 | 2.8 | 1.8 | 0.8 | 1.1 | 0.5 | 1.2 | 0.8 | 0.4 | |
OPM Ann. % | 17.8% | -10.1% | 4.43% | 4.72% | 3.42% | 2.71% | 4.00% | 7.53% | 7.23% | 6.25% | 6.35% | |
30.2% | 60.5% | 62.9 | 57.8 | 50 | 28.5 | 26.5 | 5.9 | 16.5 | 12.7 | 6.4 | ||
EBITDA Ann. | 39.7% | 43.1% | 3 | 2.9 | 1.9 | 1.1 | 1.1 | 0.5 | 1.2 | 0.8 | 0.4 | |
EBITDA Ann. margin % | 8.4% | -9.4% | 4.64% | 4.89% | 3.68% | 3.64% | 4.16% | 7.60% | 7.23% | 6.25% | 6.35% | |
Interest Ann. | -30.7% | -12.9% | 0.1 | 0.1 | 0.2 | 0.3 | 0.5 | 0.2 | 0.7 | 0.4 | 0.2 | |
Depr. | 10.1% | 32% | 0.4 | 0.4 | 0.2 | 0.3 | 0.3 | 0.1 | 0.3 | 0.3 | 0.2 | |
PBT Ann. | 71% | 65.7% | 2.5 | 2.4 | 1.5 | 0.5 | 0.4 | 0.2 | 0.2 | 0.1 | 0 | |
Tax Ann. | 44.2% | - | 0.6 | 0.7 | 0.4 | 0.2 | -0.1 | 0 | 0.1 | 0.1 | 0 | |
88.2% | 58.5% | 2 | 1.7 | 1.1 | 0.3 | 0.4 | 0.2 | 0.1 | 0.1 | |||
Net Profit Ann. | 88.2% | 58.5% | 2 | 1.7 | 1.1 | 0.3 | 0.4 | 0.2 | 0.1 | 0.1 | ||
NPM Ann. % | 43.3% | 3.9% | 3.00% | 2.81% | 2.16% | 1.02% | 1.56% | 2.48% | 0.72% | 0.53% | 0.05% | |
EPS Adj. latest Ann. | 91.3% | 60% | 2.1 | 1.8 | 1.2 | 0.3 | 0.5 | 0.2 | 0.1 | 0.1 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
8.5%
2Y CAGR
12.8%
3Y CAGR
31.1%
5Y CAGR
60.7%
7Y CAGR
26.2%
Total Revenue Annual growth is lower than historical averages.
Net Profit Ann.
1Y CHG
17.6%
2Y CAGR
34.8%
3Y CAGR
88.2%
5Y CAGR
58.5%
7Y CAGR
53.4%
Net Profit Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
8.9%
2Y CAGR
12.2%
3Y CAGR
30.8%
5Y CAGR
62%
7Y CAGR
26.6%
Operating Expenses Annual Cr growth is lower than historical averages.
Walpar Nutritions Technical Analysis
Walpar Nutritions EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 26.0 |
|---|---|
| 10 Day | 26.1 |
| 12 Day | 26.1 |
| 20 Day | 26.3 |
| 26 Day | 26.6 |
|---|---|
| 50 Day | 28.6 |
| 100 Day | 32.6 |
| 200 Day | 37.8 |
Walpar Nutritions Delivery And Volume
Daily Avg. Delivery Volume %
28 Oct, 2026100.0%
Week100.0%
Month-
Walpar Nutritions Active Candlesticks
Short Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Walpar Nutritions Resistance and Support
25.00
Pivot
| First Resistance | 25 |
|---|---|
| Second Resistance | 25 |
| Third Resistance | 25 |
| First Support | 25 |
|---|---|
| Second Support | 25 |
| Third Support | 25 |
| Day RSI | 42.7 |
|---|---|
| Day MACD | -0.6 |
| Day MFI | 35.6 |
| Day MACD Signal Line | -0.8 |
Walpar Nutritions Beta
| 1 Month | 0.5 |
|---|---|
| 1 Year | -0.3 |
| 3 Month | -0.2 |
|---|---|
| 3 Year | 0.0 |
Walpar Nutritions Price Change Analysis
↓-8.8%
Over 1 Month
LowHigh
2529
↓-28.3%
Over 3 Months
LowHigh
21.334.9
↓-32.4%
Over 6 Months
LowHigh
21.338
↓-43.2%
Over 1 Year
LowHigh
21.350.6
Walpar Nutritions Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| SHRI BAJRANGBALI ASHOK CONSTRUCTION PRIVATE LIMITED | Bulk | Sell | 14 Aug 2024 | 66.06 | 42,000 | NSE |
| TANMAYKUMAR ASHWINBHAI SHAH | Bulk | Sell | 12 Aug 2024 | 130.50 | 35,000 | NSE |
| SEJAL KALPESH LADHAWALA | Bulk | Sell | 12 Aug 2024 | 130.50 | 68,000 | NSE |
| SHRI BAJRANGBALI ASHOK CONSTRUCTION PRIVATE LIMITED | Bulk | Purchase | 12 Aug 2024 | 130.50 | 100,000 | NSE |
| PREEYESH KHANNA | Bulk | Purchase | 28 May 2024 | 129.15 | 27,000 | NSE |
| RAJESHKUMAR JANARDAN SINGH | Bulk | Sell | 23 May 2024 | 110.14 | 26,000 | NSE |
| STATSOL RESEARCH LLP | Bulk | Sell | 18 Jan 2024 | 126.75 | 24,000 | NSE |
| STATSOL RESEARCH LLP | Bulk | Purchase | 18 Jan 2024 | 126.75 | 24,000 | NSE |
| XTENDED BUSINESS REPORTING LIMITED | Bulk | Sell | 22 Aug 2022 | 55 | 8,000 | NSE |
| XTENDED BUSINESS REPORTING LIMITED | Bulk | Purchase | 22 Aug 2022 | 55.86 | 30,000 | NSE |
Walpar Nutritions Corporate Actions
Walpar Nutritions Bonus shares
Walpar Nutritions bonus history along with announcement, record, ex-bonus dates, and bonus ratios.
#Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
114 Aug 2024 | 1:1 | 14 Aug 2024 |
Walpar Nutritions Board Meetings
Walpar Nutritions past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
105 Nov 2026 | Quarterly Results and Other business matters | - |
228 May 2026 | Audited Results | - |
315 May 2025 | Audited Results | - |
412 Nov 2024 | Quarterly Results | - |
505 Jul 2024 | Bonus issue | - |
Walpar Nutritions - Company Profile
Walpar Nutritions Management Structure
Walpar Nutritions management structure with salaries, total experience, and qualifications.
Walpar Nutritions Board of Directors
Walpar Nutritions Board of directors with salaries, total experience, and qualifications.
Website: www.walparnutritions.com
About the company - Business Profile
Walpar Nutritions Ltd. is an India-based company specializing in the manufacturing and marketing of nutraceuticals, herbal, and ayurvedic products. The company operates as a contract manufacturer and also markets its own brand, focusing on health supplements and wellness products. It serves various therapeutic areas, including immunity boosters, health supplements, and lifestyle-related wellness segments.
Key Points
- Key Facts:
- Founded Year: 2009.
- Headquarters: Gandhinagar, Gujarat, India.
- Stock Listing: Listed on the NSE SME platform (Stock Code: WALPAR).
- Core Products: Tablets, capsules, syrups, and powders across Nutraceutical, Ayurvedic, and Herbal categories.
- Operations and Resources:
- The company operates a manufacturing facility in Gandhinagar, Gujarat.
- The facility is equipped to handle multiple dosage forms, including solid orals (tablets/capsules) and liquid orals (syrups/suspensions).
- Market and Significance:
- Walpar Nutritions serves the growing preventive healthcare and wellness market in India.
- It acts as a key partner for third-party brands through its contract manufacturing services, providing end-to-end solutions from formulation to packaging.
- Business Model:
- The company follows a dual business model: Contract Manufacturing (B2B) for other pharmaceutical and nutraceutical companies and Own Brand Marketing (B2C) under its own labels.
- It focuses on high-growth segments like sports nutrition, pediatric supplements, and general wellness.
- Financial Performance (FY2024-25):
- (Note: Specific segment-wise revenue splits for FY25 were not explicitly detailed in the provided search results; however, general financial trends for similar companies in the sector indicate steady growth in the domestic nutraceutical space.)
- Historically, the company has derived a significant portion of its revenue from the domestic Indian market through both institutional sales and retail distribution.
- Key Products and Technology:
- Product range includes Vitamin and Mineral supplements, Protein powders, and specialized Ayurvedic formulations for joint care, liver health, and immunity.
- The company utilizes standardized herbal extracts to ensure consistency in its ayurvedic and herbal product lines.
- Employee Count and Attrition:
- The company maintains a workforce comprising production staff, quality control experts, and a dedicated sales team. (Specific headcount figures for FY25 are not available in the summary documents).
- Strategic Initiatives and Outlook:
- Expanding the direct-to-consumer (D2C) presence through e-commerce platforms.
- Increasing the manufacturing capacity to accommodate higher volumes of third-party contract manufacturing orders.
- Exploring opportunities for exporting products to emerging markets with high demand for herbal and natural supplements.
References
